Goralatide

Goralatide is the synthetic form of AcSDKP (N-acetyl-seryl-aspartyl-lysyl-proline), an endogenous tetrapeptide cleaved from the N-terminus of thymosin-β4 by prolyl oligopeptidase. It is one of the few peptides on the market with a clean clinical paper trail — the Seraspenide oncology programme in the 1990s — and its mechanism splits cleanly into two arms: a hematopoietic stem-cell quiescence effect and a broad antifibrotic effect on TGF-β-driven collagen deposition. Both are downstream of the same molecule, and both are practically relevant to physique-focused users running long-term AAS, heavy training blocks, or post-surgical recovery.

The Thymosin-β4 → AcSDKP → ACE Axis#

AcSDKP is liberated from thymosin-β4 by prolyl oligopeptidase (POP) and then inactivated by the N-terminal catalytic domain of angiotensin-converting enzyme (ACE). This is the single most important pharmacokinetic fact about the compound: ACE is the dominant clearance route, so anything that inhibits ACE — perindopril, ramipril, lisinopril — raises plasma AcSDKP severalfold without any exogenous peptide being administered.

"Chronic ACE inhibition increases plasma AcSDKP concentration by 4-6 times in healthy humans, and up to 22 times in patients with chronic renal failure." — Azizi M. et al., Hypertension, 1999

Practically, this means an ACEi is not optional pharmacology trivia — it is the most rational thing to pair the compound with, because the minute-scale half-life of intact AcSDKP makes bolus SC injection an inefficient delivery model on its own.

TGF-β/Smad Suppression and Anti-Fibrotic Action#

The antifibrotic arm is the reason the compound shows up in cardiac and renal stacks. AcSDKP blocks TGF-β1-induced Smad2/3 phosphorylation, suppresses connective tissue growth factor (CTGF), and reduces collagen-I and collagen-III synthesis in cardiac fibroblasts. The net effect in animal models is reversal of established interstitial and perivascular fibrosis.

"Chronic treatment with Ac-SDKP significantly reduced perivascular and interstitial collagen and TGF-β1 expression in the hearts of 2K-1C hypertensive rats." — Peng H. et al., Hypertension, 2003

This matters because AAS-driven concentric LV hypertrophy is accompanied by elevated TGF-β, interstitial fibrosis, and impaired diastolic function — the exact pathology the Peng et al., 2003 protocol reverses in rodents. The mechanism is also relevant to the kidney: AcSDKP suppresses glomerulosclerosis and tubulointerstitial fibrosis in diabetic nephropathy and Ang II–driven models, which is the framing experienced users adopt when stacking it for renal protection on nephrotoxic protocols.

Endothelial-to-Mesenchymal Transition (EndMT) Blockade#

A more recently characterised arm: AcSDKP preserves endothelial identity by maintaining FGFR1 signalling in endothelial cells, preventing the switch to a mesenchymal, collagen-secreting phenotype that drives microvascular fibrosis.

"AcSDKP antagonizes the TGF‐β/Smad signaling pathway and exerts broad anti‐fibrotic effects in diabetic nephropathy and other organ fibroses." — Kanasaki K., J Diabetes Investig, 2020

When endogenous AcSDKP is experimentally lowered via POP inhibition, the opposite happens — fibrosis accelerates across cardiac, renal, and perivascular compartments (Cavasin et al., 2007). That loss-of-function evidence is the cleanest argument that endogenous AcSDKP is actively defending tissue architecture at baseline, and that supplementation is restoring a real signal rather than pharmacologically forcing one.

Hematopoietic Stem-Cell Quiescence#

The original discovery and the basis of the Seraspenide chemoprotection programme. AcSDKP reversibly holds primitive hematopoietic progenitors (CFU-S, LTC-IC) in G0/G1 and blocks their entry into S-phase. The effect is specific — it spares committed downstream progenitors and does not affect leukemic blasts.

"The tetrapeptide AcSDKP specifically blocks the cycling of primitive normal but not leukemic progenitors in long-term culture." — Bonnet D. et al., Blood, 1993

For physique users this is the least directly relevant arm, but it is mechanistically interesting in two contexts: (1) protecting the HSC compartment during prolonged inflammatory or oxidative stress (the rationale behind pulsed-dose longevity protocols), and (2) explaining why the safety record is unusually clean — the compound enforces quiescence rather than driving proliferation, so it does not carry the theoretical malignancy risk that some growth-modulating peptides do.

Pulling the Mechanisms Together#

The two arms converge on a single phenotype: AcSDKP protects long-lived, slow-cycling tissue compartments against profibrotic and proliferative stress. The TGF-β/Smad arm preserves cardiac and renal architecture under hemodynamic load. The EndMT arm protects the microvasculature. The HSC arm preserves the regenerative reservoir. For an experienced user running heavy AAS, the practical translation is straightforward — goralatide is being used as a cardiac and renal antifibrotic adjunct, ideally paired with a low-dose ACEi to stabilise plasma levels, with the post-injury / post-surgical scar-quality use-case as a secondary application alongside BPC-157 and TB-500.

Common (most users)#

• Injection-site reactions — mild erythema or transient stinging at the SC site. Rotate between abdomen, flank, and thigh; reconstitute with bacteriostatic water rather than sterile water to reduce sting.
• Transient flush or mild warmth — occasionally reported in the first 10–20 minutes post-injection, particularly when stacked with an ACE inhibitor that has already raised baseline plasma AcSDKP. Self-limiting; no dose change required.
• Mild fatigue in week 1 — usually resolves as plasma kinetics stabilise. If persistent, the dose is split into smaller AM/PM administrations rather than reduced.
• No appetite, libido, mood, or sleep effects — AcSDKP has no endocrine activity, no CNS receptor footprint, and no documented HPTA interaction. This is a non-event compound subjectively, which is part of why it is run.

Uncommon (dose-dependent or individual)#

• Reversible cytopenia at supraphysiologic exposure — the entire mechanism is HSC cycle arrest. Sustained very high plasma levels (sustained mg/kg/day infusion territory, or aggressive bolus dosing layered on top of chronic ACE inhibition in renally impaired subjects) could theoretically blunt erythropoietic and granulopoietic output. Standard antifibrotic protocols (500–2000 mcg/day SC) have not produced this in published work. CBC every 6–8 weeks on extended cycles is the conservative monitoring choice.
• Disproportionate plasma elevation when ACE inhibition is layered on — chronic ACEi raises endogenous AcSDKP 4–6× in healthy subjects and up to 22× in chronic renal failure (Azizi et al., 1999). This is the intended synergy, but in subjects with reduced eGFR the dose-response stops being linear. The protocol calls for halving the exogenous dose (250–500 mcg/day) when a full-dose ACEi is in the stack.

"Chronic ACE inhibition increases plasma AcSDKP concentration by 4-6 times in healthy humans, and up to 22 times in patients with chronic renal failure." — Azizi et al., Hypertension 1999

• Lot-to-lot variability in subjective response — at this peptide length (four residues), a single substitution or racemisation kills activity. Where a previously effective vial produces nothing, the rational move is a fresh lot with a third-party HPLC CoA rather than dose escalation.

Rare but serious#

• No serious adverse events documented in the published clinical record. The Seraspenide oncology programme ran continuous IV infusion at ~1 mg/kg/day surrounding S-phase chemotherapy without producing the kind of safety signal that would have ended the development line. The rodent antifibrotic literature at 400–800 mcg/kg/day SC for 4–8 weeks (Peng et al., 2003) is similarly clean, including no pressor or bradykinin-axis disturbance.
• Theoretical concern in occult hematologic malignancy. AcSDKP holds normal primitive progenitors in G0/G1 but does not arrest leukemic blasts in vitro:

"The tetrapeptide AcSDKP specifically blocks the cycling of primitive normal but not leukemic progenitors in long-term culture." — Bonnet et al., Blood 1993

The implication: in a host with an undiagnosed leukemic clone, sparing healthy HSCs while leaving the malignant population cycling is a non-trivial signal. Baseline CBC with differential prior to initiating a cycle is the cheap, sensible filter.

• Peptide hypersensitivity — rare for a synthetic endogenous fragment with no immunogenic motifs, but possible. Wheal, generalised urticaria, or respiratory symptoms are stop signs.

Hard contraindications#

• Active hematologic malignancy (AML, ALL, CML, MDS, lymphoma in treatment) — AcSDKP's selective sparing of normal versus leukemic progenitors is the wrong pharmacology to layer onto active disease.
• Recent hematopoietic stem cell transplant — graft engraftment depends on HSC cycling. A quiescence-inducing peptide directly antagonises that.
• Documented peptide hypersensitivity to AcSDKP or to prior tetrapeptide therapy.
• Undiagnosed cytopenia — anaemia, neutropenia, or thrombocytopenia without a worked-up cause is investigated before initiation, not after.

Gender, PCT, and stacking notes#

Goralatide is non-hormonal. No androgenic, estrogenic, progestogenic, or HPTA activity is documented, no sex-specific dose adjustment applies, and PCT is not relevant. The same 500–2000 mcg/day range applies across the full subject pool.

The ACE-inhibitor pairing (perindopril, ramipril, lisinopril) is the single most important stacking consideration — pharmacologically synergistic, supported by the human PK data, and the rational fix for the minute-scale plasma half-life. Where an ACEi is already in the cardiac-protection stack on a heavy AAS cycle, exogenous goralatide doses can be conservatively halved without losing the antifibrotic signal.